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Abstract
Background: The fourth component of human complement (C4), an essential factor of the innate
immunity, is represented as two isoforms (C4A and C4B) in the genome. Although these genes
differ only in 5 nucleotides, the encoded C4A and C4B proteins are functionally different. Based on
phenotypic determination, unbalanced production of C4A and C4B is associated with several
diseases, such as systemic lupus erythematosus, type 1 diabetes, several autoimmune diseases,
moreover with higher morbidity and mortality of myocardial infarction and increased susceptibility
for bacterial infections. Despite of this major clinical relevance, only low throughput, time and labor
intensive methods have been used so far for the quantification of C4A and C4B genes.
Results: A novel quantitative real-time PCR (qPCR) technique was developed for rapid and
accurate quantification of the C4A and C4B genes applying a duplex, TaqMan based methodology.
The reliable, single-step analysis provides the determination of the copy number of the C4A and
C4B genes applying a wide range of DNA template concentration (0.3–300 ng genomic DNA). The
developed qPCR was applied to determine C4A and C4B gene dosages in a healthy Hungarian
population (N = 118). The obtained data were compared to the results of an earlier study of the
same population. Moreover a set of 33 samples were analyzed by two independent methods. No
significant difference was observed between the gene dosages determined by the employed
techniques demonstrating the reliability of the novel qPCR methodology. A Microsoft Excel
worksheet and a DOS executable are also provided for simple and automated evaluation of the
measured data.
Conclusion: This report describes a novel real-time PCR method for single-step quantification of
C4A and C4B genes. The developed technique could facilitate studies investigating disease
association of different C4 isotypes.
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Background
The complement system is a major constituent of innate
immunity. Complement C4 plays an essential role in the
activation cascades of the classical complement pathway
as a subunit of the C3 and C5 convertases. C4 genes,
located on the short arm of chromosome 6, are present
either in a long (21 kilobasepair, kb) or in a short (14.6
kb) form, the long variant contains a 6.36 kb endogenous
retrovirus HERV-K in its intron 9 [1,2]. These genes are
deleted or duplicated together with the adjacent genes
including RP (serine-threonine kinase), CYP21 (steroid
21-hydroxylase) and TNX (tenascin-X). The set of the four
genes (RP, C4A or C4B, CYP21 and TNX) is referred to as
the RCCX module [3]. The variation of the number of
RCCX modules and sizes of the C4 genes leads to different
RCCX length forms (Fig (1)): besides the monomodular L
(long) and S (short), the bimodular (LL, LS, SS) and tri-
modular (LLL, LSS, LLS, LSL) types, the quadrimodular
version (LLLL) was also described with a very low fre-
quency. These length variants create more than 20 differ-
ent haplotype combinations.
In addition to length variations, C4 genes have two main
isotypes, C4A and C4B encoding functionally different
proteins, as C4A is more reactive with targets containing
free amino groups while C4B has a higher affinity to
hydroxyl groups [4,5]. Most individuals have the same
number of the two different C4 genes, while about 30% of
the population has a lower level of either C4A or C4B pro-
teins. The unbalanced production of C4A and C4B pro-
teins has been associated to several diseases. Complete
deficiency of the C4A or C4B gene in a haplotype module
is referred to as C4A*Q0 and C4B*Q0, respectively.
C4A*Q0, which is an essential constituent of the 8.1.
ancestral haplotype, was found to be associated with sys-
temic lupus erythematosus [6,7], insulin-dependent dia-
betes mellitus [8,9], myasthenia gravis [10], other
autoimmune diseases and abnormalities of the immune
system (reviewed in [11]). On the other hand, carriers of
the C4B*Q0 have a highly increased risk for myocardial
infarction [12], stroke [13] and an increased vulnerability
for microbial infections [14]. Interestingly autism [14]
and narcolepsy [15] have also been described to be asso-
ciated with C4B deficiency although no responsible hap-
lotype was identified.
For several decades the number of the C4A and C4B genes
has been evaluated by phenotyping, i.e. by measuring the
relative amount of the C4A and C4B proteins employing
immunofixation electrophoresis. Direct quantification of
C4A and C4B is more difficult as these genes are highly
homologous with only five isotypic nucleotide differences
[16,17]. This sequence variation can be detected by restric-
tion fragment length polymorphism (RFLP) combined
with Southern blot analysis [18]. Determination of the
RCCX module number is possible with Taq I RFLP, while
PshA I RFLP was earlier used to define the C4A/C4B ratio
[19]. Beside these techniques, there are several methods to
demonstrate of the complete absence of C4A and C4B iso-
forms. C4 null alleles with non-expressed or absent C4A/
C4B genes can be detected by high voltage agarose gel
electrophoresis of carboxypeptidase and neuraminidase
Modular variations of human complement C4 and RP-C4-CYP21-TNX (RCCX) modules in the MHC class III region Figure 1
Modular variations of human complement C4 and RP-C4-CYP21-TNX (RCCX) modules in the MHC class III 
region. Each C4 (Complement C4) gene may code either the C4A or the C4B protein, and may consist of 21 kb (long, con-
taining the HERV-K endogenous retrovirus) or 14.6 kb (short). RP: Ser/Thr protein kinase, CYP21: Steroid 21-hydroxylase, 
TNX: Extracellular matrix protein tenascin-X.BMC Genetics 2006, 7:1 http://www.biomedcentral.com/1471-2156/7/1
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treated serum or plasma samples [20], as well as by RFLP
analysis [21]. A rapid screening method was developed to
determine the main form of the C4A null allele (C4A dele-
tion) by long PCR [22]. Man and co-workers described a
polymerase chain reaction (PCR) procedure with
sequence specific primers (PCR-SSP) to determine the fre-
quency of C4A and C4B null alleles in SLE patients [23].
Real-time PCR is one of the most applicable and up-to-
date methods for DNA quantification, which allows to
track the accumulation of the PCR product during the
reaction. It provides the possibility to report the results as
a threshold cycle (CT) value, which is the cycle number
where the measured fluorescence reaches a given thresh-
old. This threshold is adjusted to the initial section of the
exponential phase of the amplification, thus the CT value
is highly proportional to the copy number of the template
DNA. Double-stranded DNA binding non-specific dyes,
such as SYBR Green or sequence-specific probes (double-
dye oligonucleotides) can be used to detect the amplified
PCR products during the reaction. Employment of Taq-
Man probes is one of the most general applications of the
latter approach, where fluorescence is generated based on
the 5' nuclease activity of the Taq  polymerase. The 3'
quencher dye of the intact probe absorbs the light emitted
by the reporter dye at the 5' end of the oligonucleotide
and emits at much longer wavelengths that is not detected
by the real-time PCR machine. On the other hand, the
DNA polymerase cleaves the TaqMan probe during the
extension step of the PCR, thus the emitted light of the
reported dye is not quenched any more [24]. One of the
most commonly used quencher dyes is TAMRA, an emerg-
ing alternative is however the employment of the MGB
(minor groove binder) probes instead, which possesses
several advantages. Although TAMRA emits at 582 nm, it
is not completely dark at those wavelengths that are
detected by the real-time PCR instruments. MGB is a non-
fluorescent "dark" quencher, moreover it stabilizes the
probe-template DNA duplex providing enhanced mis-
match discrimination and higher precision at quantitative
assays [25,26].
Here, we report a novel and rapid qPCR method for the
gene dosage determination of the complement C4A and
C4B genes. Our system employs real time PCR, and affili-
ates the two major applications of TaqMan probes: quan-
titative assay and SNP detection.
Results
Determination of the number of C4A and C4B genes
A novel robust and high throughput method was devel-
oped for C4 gene dosage determination by quantitative
real time polymerase chain reaction (qPCR). Sequence
specific TaqMan®  probes with minor groove binding
(MGB) non-fluorescent quencher were applied to deter-
mine the number of the two isotypes, the quantitative
assay of the RNase P gene was used as a reference. The
copy number of C4A and C4B genes was determined in
two separate tubes. Reaction mixture I contained the VIC-
labeled C4A-specific probe and the FAM-labeled RNase P
system, while the FAM-labeled C4B-specific probe and the
VIC-labeled RNase P reference were applied in reaction
mixture II (for sequences see Methods). To obtain the
most consistent CT values, automatic baseline and manu-
ally adjusted threshold to the lowest possible level
(approximately to 0.04 fluorescence (∆Rn) value) were
applied. The number of C4A and C4B genes (nC4A, nC4B)
was calculated according to equations (1) and (2),
The real number of C4A and C4B genes is the rounded
value of nC4A and nC4B respectively, CT(RF), CT(C4A),CT(RV)
and CT(C4B) are the determined threshold cycle values of
the FAM labeled reference (RNase P), the C4A, the VIC
labeled reference and the C4B reactions. qC4A:RF and qC4B:RV
are the efficiency quotients for VIC labeled C4A and FAM
labeled reference in reaction I, and for FAM labeled C4B
and VIC labeled reference in reaction II, respectively.
Calculation of efficiency quotients
In principle two copies of the C4A or C4B genes should
result in the same signal as that measured for the RNase P
gene, as this latter one is known to be present in a single
copy in both members of the homologous chromosome
pairs. In practice, however, the efficiency of the primers
used for the C4 and RNase P genes is not equal, moreover
additional variations are caused by the sequence differ-
ences of allele specific probes and by the application of
different dyes. Therefore, the efficiency quotients should
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Table 1: "Individual" (rows 1–7) and "overall" (last row) 
efficiency quotients (q values) and the corresponding error of 
C4A and C4B gene qunatification
PCR qC4A:RF qC4B:RV Average error
1 0.38 ± 0.03 0.64 ± 0.04 0.13
2 0.40 ± 0.02 0.71 ± 0.03 0.07
3 0.36 ± 0.04 0.67 ± 0.07 0.15
4 0.39 ± 0.03 0.70 ± 0.03 0.10
5 0.36 ± 0.02 0.66 ± 0.03 0.06
6 0.41 ± 0.03 0.67 ± 0.05 0.09
7 0.42 ± 0.02 0.65 ± 0.05 0.09
Overall 0.39 ± 0.04 0.67 ± 0.05 0.13BMC Genetics 2006, 7:1 http://www.biomedcentral.com/1471-2156/7/1
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have been determined experimentally, which was a crucial
part of our study, as the subsequent accurate genotype
determination is based on these data. This optimization
was carried out by the analysis of 65 samples in 7 separate
reactions. Applying the measured CT values the efficiency
quotients (q) could be determined based on three
assumptions: (1) too high q values could be excluded by
the simple fact that the number of the C4A or C4B gene
cannot be zero if significant fluorescence could be
detected in the appropriate reaction. (2) On the other
hand, the use of too low q values could also be avoided
because the sum of the number of C4A and C4B genes had
been described to be practically never higher than 6 in a
Caucasian population [27]. (3) The number of the C4A
and C4B genes can be only an integer. Applying equations
(1) and (2) in combination with the above assumptions
number of C4A and C4B genes of the 65 samples as well
as the accurate values of the efficiency quotients (q) have
been determined. The obtained efficiency values showed
some intra- and inter-assay fluctuation, which was proba-
bly the consequence of pipetting inaccuracy (see Table 1).
The standard deviation values depict the intra-assay error,
while the inter-assay inaccuracy is demonstrated in the
last row of the Table 1. To assess this error rate we pooled
the data of the 7 experiments and calculated overall effi-
ciency ratios for the total number of 65 samples. Based on
these results and the analyses carried out for the investiga-
tion of our Hungarian population (N = 118 samples, 11
more assays), the efficiency quotient of the C4A (VIC) and
the RNase P (FAM) reactions was found to be qC4A:RF =
0.39 ± 0.04, while that of the C4B (FAM)-RNase P (VIC)
reactions was qC4B:RV = 0.75 ± 0.11 under applied condi-
tions.
Reliability of C4A and C4B gene quantification
To analyze the reliability and reproducibility of the devel-
oped qPCR system, we investigated the error of the C4A
and C4B gene quantification by calculating either with the
Precision of the determination of the C4A and C4B gene number. Panel A: calculation by the "overall q" values, Panel B: calcu- lation by the "individual q" values Figure 2
Precision of the determination of the C4A and C4B gene number. Panel A: calculation by the "overall q" val-
ues, Panel B: calculation by the "individual q" values. The position of the squares indicate the distance of the calculated 
gene number from an integer (i.e. the error of the analysis). Green area: result is of high reliability, yellow area: acceptable 
result, red area: doubtful result. The gray bars show the number of analyzed alleles corresponding to the clusters of different 
reliability.BMC Genetics 2006, 7:1 http://www.biomedcentral.com/1471-2156/7/1
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overall q of our 7 pilot experiments or with the values
defined by each individual experiment ("individual q")
respectively. Error of the gene number quantification was
calculated as the absolute value of the difference of the
exact (equations (1) and (2)) and rounded n  values
according to equation (3).
e = |nC4 - int(nC4 + 0.5)|   (3)
where e is the error, nC4 is the calculated value of nC4A or
nC4B, and int(nC4 + 0.5) is the rounded integer. The last
column of Table 1 shows the average error of the gene dos-
age determination: rows 1–7 demonstrate the individual
values for each experiment using the "individual q-s",
while the average error obtained by using the overall effi-
ciency quotients is shown in the last row. The difference
between the two approaches is highlighted in Fig (2). The
total number of C4 gene quantifications in the pilot assays
was 129 as one of the 65 persons possessed no C4A gene.
Panel A of Fig (2) shows that applying the overall q values
for all the 129 reactions, 60% of them were in the abso-
lutely reliable range of e < 0.15, and only 8% of the results
had an e ≥ 0.3 value. If the "individual q values" of each
reaction were used, the percentage of the absolutely relia-
ble results was 83%, and the ratio of reactions with e ≥ 0.3
was 5% (Panel B of Fig (2)). As expected, the average error
is higher using the global q values. This difference was
however small enough to provide an undoubted gene
number determination as application of either the "over-
all" or the "individual" q values gave the same C4A and
C4B gene numbers for all the 65 samples. However it is
suggested to determine to "individual" q values for each
experiment by MHC.EXE and/or MHC.XLS (see below) to
achieve the highest reliability of C4 quantification.
Reliability of gene number determination in a large DNA 
concentration range
The experiment presented in Fig (3) proves that the devel-
oped qPCR is reliable practically independently of the
amount of DNA template. A quartering series of dilutions
was prepared covering the range of 0.3–300 ng genomic
DNA of a sample possessing 2 C4A and 2 C4B isotypes.
Three parallel measurements were carried out at each con-
centration. Figure 3A shows the CT values of the C4A
(VIC) and the RNase P (FAM) (reaction mixture I), 3B
demonstrates those of the C4B (FAM) and the RNase P
(VIC) reactions (reaction mixture II) as the function of the
logarithm of the relative DNA template concentration. It
can be observed that the fitted lines are practically parallel
(i.e. slope values are almost identical), moreover the R2 =
0.999 values demonstrate that the data points fit very
accurately to the lines. Based on this, any dilutions of
DNA templates resulting in CT values between 20 and 30
seem to be applicable in this genotyping system.
Application of the developed qPCR system for C4 gene 
dosage analysis in a Hungarian population
The number of C4A and C4B genes was determined by
using the elaborated qPCR in a healthy Hungarian popu-
lation (N = 118). The obtained data (Table 2, "present
work") were compared to the results of an earlier study
[28] (Table 2 "published data"), which employed the
Southern-blot based method of Blanchong et al [19]. Sta-
tistical analysis of data obtained by the novel qPCR and
by the previously applied Southern-blot analysis did not
show significant difference. In certain categories however
some discrepancy could be observed. Therefore, a set of 33
samples was analyzed by the described qPCR method, as
well as by a novel independent, capillary electrophoresis
based technology (Szilagyi et al., submitted 2005), and a
one-to-one comparison of the obtained gene dosages was
carried out. After repetition of the analysis of three sam-
ples with doubtful results, a perfect consistency of the two
methods was observed proving the accuracy of the novel
real-time PCR based methodology.
Software provided for calculations
An Excel sheet (MHC.XLS) and a stand-alone software
(MHC.EXE) were designed to improve the processing of
the measured CT values. The software reads the "csv" file
Standard curves for the C4A and C4B gene number quantifi- cation Figure 3
Standard curves for the C4A and C4B gene number 
quantification. Panel A: Standard curve of "Reaction Mix-
ture I.": VIC labeled C4A specific and FAM labeled RNase P 
specific probes, Panel B: Standard curve of "Reaction Mixture 
II.": FAM labeled C4B specific and VIC labeled RNase P spe-
cific probes. Linear regression analysis equation and coeffi-
cient of correlation are shown.BMC Genetics 2006, 7:1 http://www.biomedcentral.com/1471-2156/7/1
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created by the "Export Ct values..." function of the
Sequence Detection Software (SDS) of the Real Time PCR
Instrument of Applied Biosystems. It optimizes the q val-
ues in a default range of 0.19–1.59 for both qC4A:RF and
qC4B:RV, however these ranges can be modified by the user.
The measure of stringency ("error level") has to be
entered, and the software creates a data file containing the
C4A and C4B gene numbers and the reliability of the
results. "+++" means that e (see equation 4) is smaller
than the error level, "++" shows that e is higher than this
limit, but lower than its double. One or zero "+" shows
even higher distance of the calculated number from an
integer, in this case the gene dosages are not determined.
The software can export sample names and CT values in
the format required by the Excel sheet.
The Excel file, MHC.XLS calculates the same results in a
more user-friendly Windows based environment. In this
case the user has to type the q values, however the calcu-
lated optimal ratios are shown. Moreover red background
of these cells warns if the entered numbers are too far
away from the optimal values. In this file green, yellow
and red dots show the reliability of the calculations of the
number of the C4A and C4B genes, based on the entered
"error limit" and the same assumptions described above.
Further details about the software and the Excel sheet can
be read in their manual that can be downloaded together
with the files as "additional files of the paper".
Discussion
Real-time PCR is a useful tool for quantitative measure-
ments, thus it is readily applicable for gene expression
analyses as well as for the investigation of gene dosage
(i.e. for the determination of the copy number of different
genes in the genome or in transgenic organisms). Melo et
al. developed a real-time PCR based system for the quan-
tification of glucocorticoid receptor alpha isoform. Simi-
larly to our observation they demonstrated that the
method is reliable in a very wide template concentration
range of higher than 3 orders of magnitude [29]. Bubner
and Baldwin reviewed the use of real-time PCR for deter-
mining copy number and zygosity in transgenic plants. It
was shown that carefully optimized reaction conditions
and the application of MGB probes in combination with
the comparative method ( ) provided the possibil-
ity to detect as low as two-fold differences which is a key
issue in gene dosage analyses [25].
There are two methods to monitor the amount of the
PCR-products during the reaction: the application of
intercalator dyes (e.g. SYBR Green) demonstrate the pres-
ence of the double stranded DNA, thus it can be used in
any system. The design and employment of sequence spe-
cific probes (e.g. TaqMan) is the other approach. Besides
the accurate and specific quantification of the PCR prod-
uct of interest this method is readily applicable to detect
as small as a single base change in the DNA sequence thus
it can be used for SNP genotyping [24,30]. These two
ideas were combined in our system developed for the
determination of the number of C4A and C4B genes.
There are only 5 isotypic base changes in a 17-bp-long
sequence of the two genes differentiating them from each
other (see Fig (4)). C4A and C4B specific TaqMan probes
were designed covering four of these SNPs, and the two
probes were labeled with different dyes (VIC and FAM
respectively). Although we optimized the presented qPCR
method as a two-tube-system for the accurate quantifica-
tion of the C4 genes, the purpose of labeling the two Taq-
Man probes with different dyes was to provide a further
possible application for large-scale screening. It is a single-
tube-approach, where the C4 specific probes are used in
the same reaction and no RNase P reference is applied.
2−∆∆CT
Table 2: C4A and C4B gene dosage in a healthy cohort determined by the presented qPCR method. Comparison to earlier data 
obtained by Southern-blot analysis [28]
C4A genes C4B genes
Gene dosage Present work Published data Gene dosage Present work Published data
Number (%) Number (%)
0 2 (1.7) 2 (1.6) 0 1 (0.8) 1 (0.8)
1 18 (15.3) 26 (20.3) 1 24 (20.3) 26 (20.3)
2 65 (55.1) 73 (57.0) 2 75 (63.6) 90 (70.3)
3 30 (25.4) 24 (18.8) 3 18 (15.3) 10 (7.8)
4 3 (2.5) 3 (2.3) 4 0 (0.0) 1 (0.8)
Total 118 (100) 128 (100) 118 (100) 128 (100)
χ2 test p = 0.7023 p = 0.3632BMC Genetics 2006, 7:1 http://www.biomedcentral.com/1471-2156/7/1
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Although in this case only the ratio of the number of C4A
and C4B genes can be determined, the system is of double
throughput, as only three (and not six) parallel measure-
ments are necessitated. This simplified technique is suita-
ble for preliminary screening as well as for the
determination of the lack of the C4A or C4B isotype,
whereas the double-tube system described in detail is to
be used for the determination of the definite number of
the C4 genes.
The quantification of C4A and C4B genes is of great clini-
cal as well as theoretical importance, because either the
deficiency or the exceeding amount of any of the two C4
variants may adversely influence immune processes.
Although the sequence of the two isoforms differs in less
than 1%, this variance alter their hemolytic and serologi-
cal reactivity as well as their affinity to antigens and
immune complexes [27]. The disease association of the
C4A*Q0 or C4B*Q0 phenotypes have been widely inves-
tigated. C4A*Q0, an essential constituent of the 8.1 ances-
tral haplotype [11] was found to be related to systemic
lupus erythematosus [31-34], Graves' disease [35] and
systemic sclerosis [36]. In contrast the association of the
C4B*Q0 and shorter life-expectancy [37], increased sus-
ceptibility for myocardial infarction [12], stroke [13],
autism [38], Henoch-Schonlein purpura glomerulone-
phritis [39], bacterial meningitis[40], angio-oedema and
"lupus-like" disease [41], and bacteremia with encapsu-
lated organisms [42] and meningococcal disease [43] was
also described.
This wide range of diseases underlines the relevance of a
simple and high throughput method for C4 gene dosage
analysis to improve our knowledge about the role of func-
tionally different isotypes in physological as well as in the
above mentioned pathological immune procedures. RFLP
and gel electrophoresis based methods developed earlier
[18,20] are of low throughput, moreover they are techni-
cally difficult and labor intensive. RFLP analysis in combi-
nation with Southern-blot is the only method at present
which is suitable for characterization of the whole RCCX
module, but it requires a large amount of DNA and the
employment of radioisotopes.
Our report presents a rapid qPCR technique for the deter-
mination of the number of C4A and C4B genes. The
developed method is a single step procedure, where no
subsequent post-PCR analyses are required. Computa-
tional applications are also provided for automated allele-
calling procedure, which makes the evaluation of the
results fast, simple and reliable. The determined C4 gene
dosages were compared to the data of an earlier study that
investigated the same group of healthy Hungarian sub-
jects applying Southern blot for C4A and C4B gene quan-
tification. Moreover 33 samples were analyzed by two
independent methods. There was no significant difference
between the results of these studies underlining the accu-
racy of our novel method. Although the demonstrated
technique has some limitations, for example it is not suit-
able for the identification of the non-functional C4 genes
caused by 1- or 2-bp-deletions [44], this comprehensive
system could facilitate the investigation of complement
C4A and C4B genes in the future.
Methods
Genomic DNA was isolated from peripheral blood using
the Flexigene DNA isolation kit (Qiagen). Primers and
fluorogenic probes for the 5' nuclease assay were designed
by the Primer Express software. Fig (4) shows a short seg-
ment of the sequence of complement C4B gene [Gen-
Bank:U24578] demonstrating the position of the primers
(arrows) and the TaqMan probe. The black boxes indicate
those nucleotides that are different in the two isoforms,
this sequence variation was used to design the C4A and
C4B specific probes. For quantifying the C4A and C4B
genes two separate reactions were used, three parallels
were carried out for each measurement. Both reaction
mixtures contained 6 µM forward (5' GCA GGA GAC ATC
TAA CTG GCT TCT 3') and 6 µM reverse (5' CCG CAC
CTG CAT GCT CCT 3') primer (see Fig (4)), 1× TaqMan
Universal PCR Master Mix (AmpliTaq Gold®  DNA
Polymerase, dNTPs with dUTP, Passive Reference, No
AmpErase UNG®) and genomic DNA template. Reaction
mixture I contained furthermore the C4A specific TaqMan
probe (5' VIC-ACC CCT  GTC CAG TGT TAG-MGB 3';
MGB: minor groove binding non-fluorescent quencher)
and the FAM-labeled 1× RNase P Detection Mix (ABI Cat.
No. 4316831), while the FAM-labeled C4B specific Taq-
Man probe (5' FAM-ACC TCT CTC CAG TGA TAC-MGB
3') and the VIC-labeled 1× RNase P Detection Mix (ABI
Cat. No. 4316844) was added to reaction mixture II in a
total volume of 25 µl. (The bold and underlined letters
show the sequence differences of the two probes corre-
sponding to the nucleic acid variations that distinguish
Position of TaqMan probe and primers for C4 gene number  analysis Figure 4
Position of TaqMan probe and primers for C4 gene 
number analysis. A short part of the C4B gene is shown 
[GenBank:U24578]. Arrows: position of the primers, under-
lined sequence with FAM at 5' end and MGB at 3' end: posi-
tion of the TaqMan probe. White letters in black boxes: 5 
single nucleotide polymorphisms distinguishing the C4A and 
C4B genes.BMC Genetics 2006, 7:1 http://www.biomedcentral.com/1471-2156/7/1
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the C4A and C4B genes.) DNA amplification was carried
out in an ABI 7500 Real Time PCR System. Thermocycle
was initiated by incubating the mixtures at 95°C for 10
minutes to denature genomic DNA and to activate Ampl-
iTaq Gold® DNA Polymerase. This was followed by 40
cycles of two steps of 95°C for 15 sec and 60°C for 1
minute, the fluorescence intensity was measured during
the step of 60°C.
DNA samples of 173 healthy Hungarian individuals were
used for the present study. These individuals participated
in a regular medical survey and gave their informed con-
sent for the use of their sample for the study. For ethical
reasons after their computer registration the data were
unlinked from the subjects so their identities could not be
traced. The study was approved by the Ethical Committee
of the Semmelweis University (Budapest, Hungary)
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